Ro's home diagnostics moat

Ro is turning telehealth from a one time online prescription flow into a home based care system that can handle chronic treatment. The point of buying diagnostics, fertility testing, and in home phlebotomy is to own the steps between intake and refill, so Ro can order labs, collect samples, review results, change dosing, and ship medication without sending patients out to separate labs, clinics, or courier networks.1 2 3

• This matters most in categories like GLP-1s and hormones, where care is not just writing a script. Patients need baseline labs, repeat testing, dose changes, side effect checks, and ongoing messaging. Ro built around that by combining Workpath, Kit, Modern Fertility, its own lab, and six owned pharmacies.1
• The contrast is with earlier D2C telehealth models built on simple, high churn products like ED meds. Those could stay asset light because the workflow was a short questionnaire and a refill. More complex care needs tighter operational control, which is why Ro moved deeper into the stack while peers like Hone also built around recurring blood work and monitoring.1 2 4
• There is also reuse value across conditions. A home blood draw network or hormone testing capability does not only support fertility or obesity. It can be plugged into women’s health, testosterone, longevity, and other longitudinal programs, similar to how Function uses testing infrastructure as the base layer for additional services.1 2 3

The next phase is that home diagnostics and care logistics become the moat, while basic prescribing gets cheaper and more interchangeable. As drug access commoditizes, the winners in telehealth will be the companies that can run ongoing care loops across many conditions from one consumer entry point, and Ro has been building exactly that operating layer.1 3